The mRNA Cancer Vaccine: The Dawn of Personalised Oncology
A Vaccine Made for One Person

Traditional vaccines prepare the immune system to recognise a particular pathogen. A personalised cancer vaccine has a very different target: the mutations inside one specific patient’s tumour.
Every cancer is genetically different. As tumour cells multiply, they accumulate mutations, producing abnormal proteins that healthy cells do not make. Some of these mutated proteins, known as neoantigens, can act like molecular fingerprints for cancer. Intismeran is designed around those fingerprints.
Doctors take a sample of the patient’s tumour and sequence its genetic material. Algorithms identify mutations that could produce useful neoantigens. Scientists then create an mRNA sequence encoding those targets. That sequence becomes the blueprint for a vaccine manufactured specifically for that patient.
Once injected, the mRNA instructs cells to temporarily produce the selected tumour-associated targets. The immune system encounters them and mounts a response, effectively receiving a molecular lesson in what that patient’s cancer looks like.
The resulting immune response can then hunt for cancer cells carrying those same mutations. The extraordinary part is the level of customisation. Instead of searching for one universal cancer target, medicine can now build the target around the tumour sitting inside a particular patient.